Otelixizumab Terminated Phase 2 Trials for Type 1 Diabetes Mellitus Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01222078Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
NCT00451321TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)